Qiaoping Xu

7PUBLICATIONS
15CO-AUTHORS
Cancer diagnosisCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|May 13, 2026
Pyruvate carboxylase promotes SREBP1a-mediated lipid synthesis in epithelial ovarian cancer.

|Apr 16, 2026
Cost-effectiveness of pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma.

|Dec 10, 2025
Cost-effectiveness of sugemalimab plus chemotherapy as first-line therapy in advanced gastric cancer and gastroesophageal junction cancer.

Jiaming Zhu, Zhengxiong Li, Qiaoping Xu

|Nov 18, 2025
Response to Corcept's retraction request on manuscript of "Relacorilant plus nab-paclitaxel for recurrent, platinum-resistant ovarian cancer: a cost-effectiveness study".

Qiaoping Xu

|Aug 28, 2025
Cost-effectiveness of talazoparib plus enzalutamide as first-line therapy in metastatic castration-resistant prostate cancer.

Jiaming Zhu, Zhengxiong Li, Ye Ding

|Mar 07, 2025
Relacorilant plus nab-paclitaxel for recurrent, platinum-resistant ovarian cancer: a cost-effectiveness study.

Yidong Zhou, Fei Tong, Bowen Jin

Pageof 2

Frequent Collaborators

2 joint publications

Zhengxiong Li

2 joint publications

Jiaming Zhu

1 joint publications

Changrong Wang

1 joint publications

Jiangli Du